Last reviewed · How we verify
Memantine (once daily)
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity. Used for Moderate to severe Alzheimer's disease.
At a glance
| Generic name | Memantine (once daily) |
|---|---|
| Also known as | Lu 00-800, Ebixa ®, Ebix ® |
| Sponsor | H. Lundbeck A/S |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivity of glutamate signaling while preserving normal synaptic transmission. This mechanism protects neurons from excitotoxic damage thought to contribute to cognitive decline in neurodegenerative diseases. The drug is thought to restore a more normal balance of glutamatergic neurotransmission in the brain.
Approved indications
- Moderate to severe Alzheimer's disease
Common side effects
- Dizziness
- Headache
- Confusion
- Constipation
- Hypertension
- Fatigue
Key clinical trials
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- The Use of Memantine for Prevention of Alzheimer's Disease (PHASE2)
- Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia (PHASE3)
- Memantine Hydrochloride in Prostate Cancer Patients (PHASE2)
- A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer (PHASE2, PHASE3)
- Ozanimod in Patients With Alzheimer's Disease (PHASE2)
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases (PHASE3)
- Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Memantine (once daily) CI brief — competitive landscape report
- Memantine (once daily) updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI